FB-1603
/ Febico Biomedical
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 27, 2025
To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
(clinicaltrials.gov)
- P1/2 | N=120 | Recruiting | Sponsor: Febico Biomedical Corp. | Trial completion date: Aug 2025 ➔ Aug 2027 | Trial primary completion date: Jun 2025 ➔ Jun 2027
Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor
June 27, 2024
To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
(clinicaltrials.gov)
- P1/2 | N=120 | Recruiting | Sponsor: Febico Biomedical Corp.
New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1